ILM peeling beneficial, not harmful

Article

Peeling the internal limiting membrane (ILM) may reduce the rate of premacular fibrosis (PMF) formation, according to a study published in the June 2008 issue of Retina.

Peeling the internal limiting membrane (ILM) may reduce the rate of premacular fibrosis (PMF) formation, according to a study published in the June 2008 issue of Retina.

Ramin Schadlu, MD of the Department of Ophthalmology and Visual Science at Washington University of St Louis, US and colleagues conducted a retrospective chart review to establish the rate of favourable outcomes after surgical ILM peeling to remove PMF. Patients undergoing pars plana vitrectomy (PPV) and ILM peeling (n=38) had visual acuity assessed before and three months after surgery. Complications and PMF recurrence were noted.

Patients with higher presurgical visual acuity had the most favourable outcomes, with no adverse events and high postsurgical visual acuity. Following surgery, visual acuity remained the same or improved in 89.5% of treated eyes. Visual acuity improvement averaged 2.2 lines. PMF recurred in 2.6% of treated eyes (n=1). Cataract formation was the most common adverse event; following extraction, two patients developed cystoid macular oedema (CME).

The researchers concluded that the rate of adverse events associated with ILM peeling was not as high as previously believed and that, within this group of patients, outcomes were not unfavourable.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.